Tredu. Expert Education. Smarter Trading.

Mastering Equity and Stock Trading, Cryptocurrency Investment, Digital Assets and Global Forex Market Analysis: The Ultimate Masterclass at Tredu

Gain access to expert-led courses, live market analysis, and educational webinars that turn complex concepts into actionable strategies.Learn how to trade smarter and join our community of successful traders, building sustained financial growth.

Financial News

Maintain market dominance with real-time updates and expert analysis.
Our educators provide focused coverage across stock trading, forex markets, and crypto investing. We translate the latest financial news into practical knowledge, empowering you to trade smarter and achieve superior execution.

Proprietary Trading Strategies and
Quantitative Analysis

Sharpen your execution skills and gain a decisive edge with in-depth insights delivered by our top trading educators. Explore proven trading strategies, anticipate current market trends, and leverage expert analysis specifically designed to support your trading education and accelerate your path to sustained market success.

Tredu Team | Insights

CRISPR Therapeutics AG (NASDAQ: CRSP) Sees Promising Future Despite Challenges

CRISPR Therapeutics AG (NASDAQ: CRSP) Sees Promising Future Despite Challenges

Geulah Livshits from Chardan Capital sets a price target of $76 for CRSP, indicating a potential increase of 43.21%. CRISPR Therapeutics' gene-editing therapy, Casgevy, for sickle cell disease receives FDA approval, showcasing the company's innovative potential. Despite a fourth-quarter loss, CRSP's stock rose by 8.46% due to its collaboration with Vertex Pharmaceuticals and the growing adoption of Casgevy therapy. CRISPR Therapeutics AG (NASDAQ: CRSP) is a leading biotech company specializing in gene editing. The company has gained attention for its innovative CRISPR-based technology, which allows for precise gene editing to treat diseases. CRISPR Therapeutics has already commercialized its technology, offering a revenue stream and potential for future growth. Its main competitor in the gene-editing space is Editas Medicine. On February 14, 2026, Geulah Livshits from Chardan Capital set a price target of $76 for CRSP, suggesting a potential increase of 43.21% from its February 13 closing price of $53.07. This optimistic outlook is supported by CRISPR Therapeutics' recent achievements, including the FDA approval of its gene-editing therapy, Casgevy, for sickle cell disease. The approval highlights the company's potential to revolutionize treatment options. Despite reporting a disappointing fourth quarter with a loss of $1.37 per share and total revenue of only $864,000, CRSP's stock rose by 8.46%. This unexpected increase is largely due to its collaboration with Vertex Pharmaceuticals, which also saw a stock increase of 6.51%. The partnership strengthens CRISPR Therapeutics' position in the biotech industry and enhances its growth prospects. CRISPR Therapeutics' Casgevy therapy generated $54 million in revenue during the fourth quarter of 2025 and $116 million for the entire year. The therapy's adoption is growing, with 147 patients beginning treatment in 2025, nearly tripling from the previous year. This expansion is expected to drive higher revenue in 2026, as noted by William Blair, who highlighted the increase in patient initiations. The stock for CRSP closed at $53.07 on February 13, reflecting an 8.46% increase from the prior day. It fluctuated between $49.62 and $54.10 on February 13, with a market capitalization of approximately $5.09 billion. The trading volume was 2,465,000 shares on the NASDAQ exchange. Despite challenges, CRISPR Therapeutics' innovative technology and strategic partnerships position it for potential growth.

Tredu Team | Insights

Planet Ventures Inc. (OTC:PNXPF) Announces Reverse Stock Split

Planet Ventures Inc. (OTC:PNXPF) Announces Reverse Stock Split

Planet Ventures Inc. (OTC:PNXPF) is set to undergo a reverse stock split on February 20, 2026. This Canadian company, which operates in the venture capital sector, will consolidate its shares on a two-for-one basis. This means shareholders will receive one new share for every two they currently hold. Despite this change, the company's name and stock symbol will remain unchanged. Before the consolidation, Planet Ventures has 304 million common shares issued and outstanding. Post-consolidation, this number will be reduced to approximately 152 million shares. This reduction in the number of shares is expected to streamline the company's share structure. The new CUSIP number for the post-consolidation shares will be 727053308, and the new ISIN will be CA7270533085. The reverse stock split is a strategic move approved by the company's board of directors. However, it is still pending approval from the Canadian Securities Exchange. Once approved, Planet Ventures will provide further details regarding the effective date of the consolidation. This move is part of the company's efforts to enhance its market position. Currently, PNXPF is trading at $0.163, reflecting a decrease of 8.32% with a change of -$0.014. The stock's price today has ranged from a low of $0.163 to a high of $0.167. Over the past year, PNXPF has reached a high of $0.25 and a low of $0.014. The company's market capitalization stands at approximately $33.27 million, with a trading volume of 30,500 shares on the OTC exchange.

Tredu Team | Insights

TRI Pointe Homes, Inc. (NYSE: TPH) Downgrade Amid Sale Investigation

TRI Pointe Homes, Inc. (NYSE: TPH) Downgrade Amid Sale Investigation

Oppenheimer downgraded NYSE:TPH from "Outperform" to "Perform" due to an ongoing investigation into its proposed sale. Shareholders are set to receive $47 per share in cash, reflecting a 26.80% increase in stock price. The company's market capitalization stands at approximately $3.99 billion, with a trading volume of 22.31 million shares. TRI Pointe Homes, Inc. (NYSE:TPH) is a leading homebuilding company in the United States, specializing in the design, construction, and sale of single-family homes. The company operates across several states, offering a variety of home designs and price points, and competes with major homebuilders like Lennar Corporation and D.R. Horton, Inc. On February 13, 2026, Oppenheimer downgraded NYSE:TPH from an "Outperform" to a "Perform" rating. At the time, the stock price was $46.37. This downgrade comes amid an ongoing investigation by Monteverde & Associates PC into TRI Pointe's proposed sale to Sumitomo Forestry Co., Ltd. The investigation seeks to ensure the fairness of the sale terms for shareholders. TRI Pointe shareholders are set to receive $47 per share in cash as part of the proposed sale. The current stock price of $46.37 reflects a significant increase of 26.80%, with a change of $9.80. The stock has fluctuated between $46.25 and $46.46 today, marking its highest price over the past year. The lowest price in the past year was $27.90. The company's market capitalization is approximately $3.99 billion, indicating its size and value in the market. Today's trading volume for NYSE:TPH is 22.31 million shares, showing active investor interest. The investigation by Monteverde & Associates, led by Class Action Attorney Juan Monteverde, aims to protect shareholder interests in the proposed sale.

Connect with Verified Trading
Educators for Tailored Mentorship
Across All Trading Styles

ADVANCED SEARCH

108 results

Top Brokers

Secure Your Trading Journey with the Right Broker

Advertisement for tredu.com - trading platform

Proud Media Partners of

Cyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumCyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation Forum